 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > Centaur Pharmaceuticals, Inc.
 |
Centaur Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
Centaur Pharmaceuticals is developing nitrone-related therapeutics (NRTs) to treat strokes and such illnesses as Parkinson's disease, AIDS dementia, and Alzheimer's disease. These conditions involve stress agents, such as the cell-damaging oxygen agents called free radicals, which Centaur hopes to neutralize with its oral and intravenous drug candidates. Centaur Pharmaceuticals is also investigating the use of its NRT technology to treat arthritis, inflammatory bowel disease, heart attacks, and other conditions. The firm has a research and marketing pact with AstraZeneca for its stroke and Alzheimer's treatments.
COMPETITION |
 |
Amgen Inc. (AMGN)
Cortex Pharmaceuticals, Inc. (COR)
NeoTherapeutics, Inc. (NEOT)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 7.10
1-Yr. Sales Growth: (26.0)%
Employees: 73
Revenue per employee: $97,260.27
KEY PEOPLE |
 |
Paul L. Wood
CEO
Lucy O. Day
CFO
CONTACT INFO |
 |
1220 Memorex Dr.
Santa Clara, CA 95050
US
Phone: 408-822-1600
Fax: 408-822-1601
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |